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Background: Copy number variations (CNVs) and DNA sequence alterations affecting specific neuronal genes are
established risk factors for Autism Spectrum Disorder (ASD). In what is largely considered a genetic condition, so far,
these mutations account for ~20% of individuals having an ASD diagnosis. However, non-coding genomic
sequence also contains functional elements introducing additional disease risk loci for investigation.
Results: We have performed genome-wide analyses and identified rare inherited CNVs affecting non-genic intervals
in 41 of 1491 (3%) of ASD cases examined. Examples of such intergenic CNV regions include 16q21 and 2p16.3 near
known ASD risk genes CDH8 and NRXN1 respectively, as well as novel loci contiguous with ZHX2, MOCS1, LRRC4C,
SEMA3C, and other genes.
Conclusions: Rare variants in intergenic regions may implicate new risk loci and genes in ASD and also present
useful data for comparison with coming whole genome sequence datasets.
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Newer genomic technologies like high-resolution micro-
arrays and next generation exome sequencing have en-
abled the identification of many clinically relevant genetic
variants for both Mendelian and complex disorders. Yet
for many conditions the identified genes account for only
a proportion of heritability. This observation coupled with
the recognition of the functional relevance of non-genic
regions [1] target these genomic segments as candidates
for investigation for a role in disease.
ASD encompasses a range of neurodevelopmental disor-
ders characterised by social impairment, communication
difficulties and restricted, repetitive behavioural patterns.
ASD, which is clinically and genetically heterogeneous,
demonstrates high heritability, familial clustering and ~4:1
male to female bias. While there has been progress iden-
tifying risk genes, most are still unknown [2]. Analyses
of rare (<1% population frequency) CNVs, insertions
and deletions (indels) and point mutations have most
convincingly identified synaptic genes such as members* Correspondence: Stephen.Scherer@sickkids.ca
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distribution, and reproduction in any mediumof the Neuroligin (NLGN3, NLGN4) [3], Neurexin
(NRXN1 [4], NRXN2 [5], NRXN3 [6]), SHANK (SHANK1
[7], SHANK2 [8], SHANK3 [9]) families and Gephyrin
[10] as highly-penetrant risk loci [2]. ASD subjects with
multiple genetic risk factors for ASD and associated med-
ical conditions are also known [11]. In addition, there are
a few examples of mutations in ASD cases identified in
non-genic segments of DNA [12] and non-coding RNAs
[13]. Similar findings are even better documented in
studies of intellectual disability [14,15], which is observed
in ~40% of cases of ASD. Focusing on the intergenic inter-
vals of the genome, we performed a systematic genome-
wide investigation to identify rare CNVs enriched in cases
compared with controls [16] to identify known and novel
ASD susceptibility loci.
Methods
A collection of 1491 unrelated ASD cases were genotyped
using either the Illumina 1M (993) or the Affymetrix SNP
6.0 platforms (498). The ASD subjects, all diagnosed using
gold-standard instruments including Autism Diagnostic
Interview and Autism Diagnostic Observation Schedule,
are described elsewhere [16,17]. Informed written consent
was obtained from all participants, as approved by the
Research Ethics Boards at The Hospital for Sick Childrenentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.






































































Figure 1 (See legend on next page.)
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Figure 1 Genome browser views of ASD specific CNVs at A) 2p16.3 B) 11p12 C) 8p12 and D) 4q13.1. In each case, representative isoforms
of known RefSeq genes, mRNA and/or Expressed Sequence Tags are shown. Deletions and duplications are represented by red and blue bars,
respectively. In Figure 1A) a dashed line indicates a diploid region located between two adjacent deletions in the same individual. Additional
browser views from other loci shown in Table 1 are included in Additional file 1 A-J. In all cases where parental DNA was available, the CNVs
shown were found to be inherited. Additional case SK0167-003 found in Marshall et al. [19].
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the SAGE cohort were genotyped on with the Illumina 1M
and 1234 samples from the Ottawa Heart Institute (OHI)
and 1123 from the POPGEN collections were genotyped
on the Affymetrix SNP 6.0. CNV discovery was performed
using previously described pipelines [16-18]. Three CNV
detection tools were used for each platform (Birdsuite,
iPattern and Genotyping Console for Affymetrix 6.0
and iPattern, QuantiSNP & PennCNV for Illumina 1 M).
A subset of CNVs in both cases and controls were consid-
ered rare if they were present in <1% of the overall dataset
and these were further analysed if they failed to intersect
or fall within a known gene (according to the NCBI Refer-
ence Sequence (RefSeq), August 2011). Rare genic CNVs
identified from these data have been reported previ-
ously and from these data approximately 10% of cases
carry a de novo or rare inherited CNV thought to
contribute to ASD in that individual [16,17,19,20]. All
CNVs discussed were validated where DNA was avail-
able using independent laboratory methods such as
long range or quantitative PCR and the mode of inher-
itance determined (Additional files 1 and 2).
Results and discussion
Microarray data from a cohort of 1491 unrelated ASD
probands were analysed for rare copy number variants
as described previously [16,17] and CNVs falling outside
of known coding sequence were identified. A total of
212 non-coding genomic regions were determined as
harboring overlapping CNVs in two or more unrelated
ASD cases that were absent in control samples. Each
region was examined for plausible biological function by
comparison with multiple databases. Data was collated
for evidence of expressed sequences from mRNA or EST
data at GenBank or evolutionary conservation as well as
functional predictions from the VISTA enhancer browser
(http://enhancer.lbl.gov/) and Rfam (http://rfam.sanger.ac.
uk/). The Database of Genomic Variants (http://dgvbeta.
tcag.ca/dgv/app/home) was used to eliminate additional
regions as non-ASD specific CNVs and regions with >80%
masked as repetitive sequences were removed. Loci were
also prioritised as being of potential clinical significance
in ASD due to proximity to genes considered known or
candidate ASD risk genes [17].
Fifteen intergenic regions emerged as plausible candi-
date ASD risk loci and in all instances the defining CNV
events were inherited. In one of these regions, anadditional case (SK0167-003) was found with an overlap-
ping CNV described by Marshall et al. (2008) [19]
(Table 1, Figure 1 and Additional files 1 and 2). In 14 of
15, the intergenic interval identified has not been de-
scribed before and in three regions the CNV
neighboured a known ASD gene, namely, CDH8 [21],
C3orf58 [22] and NRXN1 [4]. In the case of the NRXN1
gene, upstream CNVs found in five individuals impact
the same mRNA (AK127244) reported elsewhere with a
CNV in a family with ASD (Table 1, Figure 1A) [23]. Ex-
amples of other intergenic CNVs identified highlight re-
gions at 8q24.12 upstream of ZHX2, 6p21.2 upstream of
MOCS1, 11p12 upstream of LRRC4C (Figure 1B) and
7q21.11 upstream of SEMA3C, as putative novel ASD
rearrangements. In one case (8-14208-3350), deletions
were identified at three separate loci; 4q13.1 upstream
of EPHA5, 11p14.3 upstream of LUZP2 and 11p12 up-
stream of LRRC4C and another case (3-0496-003) car-
ried a 46, XXY sex chromosome imbalance. Other
CNVs found in these 41 cases are shown in Additional
file 3 and any or all of these may be contributing to the
genetic load for ASD [11,17]. Interestingly, all the
CNVs identified through our analysis are inherited
events. The significance of this observation is still to be
determined but suggests incomplete and/or variable
penetrance of phenotype, which is something often ob-
served in ASD [6,7,17].
The mechanism of action of these rare CNVs in the
pathogenesis of ASD could be (i) through altering the
necessary copy number or positional context of key DNA
sequence elements required for regulating the proper
expression of nearby genes [1], (ii) affecting still undis-
covered genes or non-coding RNAs residing in the CNV
regions and (iii) disrupting uncharacterized isoforms of
the adjacent annotated genes. In the first scenario, we find
CNVs both upstream (e.g. UNC5D (Figure 1C), MOCS1,
ASTN2, SEMA3C, ZHX2, LUZP2, CDH8) and down-
stream (C3orf58, RXRA, MRGPRD) of known ASD risk
genes and putative novel loci. For at least three regions
(4q13.1, 6p21.2 and 11p12 (shown in Figure 1D, Additional
file 1C and Figure 1B respectively)), our CNV mapping
data in fact identify two distinct clusters of CNVs at the
same locus, all overlapping spliced ESTs and thus with a
possible regulatory role. Secondly, three independent
CNV deletions interrupting a collection of spliced ex-
pressed sequenced tags approximately 330 kb proximal
to EPHA5 highlight a potentially newly discovered ASD
Table 1 ASD specific CNVs in intergenic regions
Locus Gene Sample CNV Start End Size Furthest distance
from gene
Bin
2p16.3 NRXN1 AK127244 mRNA 1-0045-004 loss 51405882 51524684 118802 1124 ii
8-3394-003 loss 51439897 51479683 39786
8-3394-003 loss 51157414 51189362 31948
8-14144-2420 loss 51157414 51225851 68437
1-0496-003 gain 52220120 52238172 18052
1-0449-003 loss 52237072 52253660 16588
3p22.3 ARPP21 2-1213-003 loss 34984049 35102773 118724 563 ii
3-0100-000 gain 35086691 35094736 8045
3q24 C3orf58 ZIC1, ZIC4 1-0007-003 loss 146168760 146934953 766193 1383 1955, 1979 i
8-3093-004 loss 146575437 146631141 55704
4q13.1 EPHA5 8-14208-3350 loss 66505324 66633530 128206 840 i
8-14186-3050 loss 66515708 66633530 117822
1-0138-004 loss 66515708 66633530 117822
2-0082-004 loss 67045815 67134170 88355
1-0455-003 loss 67058506 67075558 17052
6p21.2 MOCS1 3-0139-000 gain 40021898 40078515 56617 168 i or ii
2-0139-003 gain 40023327 40062155 38828
1-0381-003 loss 40174188 40209324 35136
2-1368-003 loss 40174188 40210694 36506
7q21.11 SEMA3C 8-6258-03 loss 80431202 80512022 80820 96 i
1-0345-005 loss 80482597 80517630 35033
8p12 UNC5D NRG1 8-14243-3670 loss 34923482 34956067 32585 256 2183 i
3-0044-000 loss 34923482 34956067 32585
3-0300-000 loss 34925149 34957854 32705
8-14181-2940 loss 34923482 34956067 32585
8q24.13 ZHX2 8-3317-003 gain 123572785 123625681 52896 237 i or ii
3-0186-000 loss 123583028 123639417 56389
9q33.1 ASTN2 8-3055-004 loss 119254497 119374796 120299 98 i
3-0115-000 loss 119314967 119319559 4592
9q34.2 OLFM1 RXRA 2-1272-003 gain 136479329 136604233 124904 508 8 i
2-1189-003 gain 136480334 136598491 118157
11p14.3 LUZP2 8-14175-2820 loss 24177612 24316053 138441 160 i or ii
8-14059-1020 loss 24262511 24303132 40621
8-14208-3350 loss 24262511 24303132 40621
11p12 LRRC4C 8-14208-3350 gain 40304880 40703298 398418 196 iii
2-0272-003 loss 40379668 40550356 170688
SK0167-003 loss 40417554 40610400 192846
3-0208-000 loss 40468058 40492541 24483
11p12 LRRC4C 8-14032-600 loss 41990280 42021250 30970 1738 i or ii
8-3276-003 loss 42243624 42279094 35470
2-0286-003 loss 42243624 42279094 35470
11q13.2 MRGPRD 4-0023-003 loss 68486121 68493638 7517 10 i
2-1075-003 loss 68486121 68500238 14117
16q21 CDH8 8-14251-3750 loss 61650435 61787984 137549 1030 i or ii
2-1175-003 loss 61658675 61755232 96557
Location and size of all CNVs discovered are listed with the proposed associated candidate gene. Bin denotes possible mechanism of action by i) altering sequence elements
required for regulating expression of neighboring genes ii) affecting undiscovered genes or non-coding RNAs iii) disrupting uncharacterised isoforms of adjacent genes. Genome
browser views of all loci are shown in Figure 1 and Additional file 1. All pedigrees are shown in Additional file 2. Additional sample SK0167-003 identified in reference [19].
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LRRC4C likely exist given the discovery of mRNAs
DQ084201 and DQ084202. There are, of course, other
functional DNA elements or modifications that need to
be considered [24] as the mapping resolution increases.
Conclusions
Given the challenges faced in interpreting the clinical
significance of multitudes of genetic variants found in for
example, whole genome sequencing [25], accruing evi-
dence across multiple studies will advocate loci outside of
known genes or other regulatory elements for further
study, particularly for rare variants. In this light, these data
provide a useful resource for comparison as new data sets
of both CNVs and nucleotide-level variants become avail-
able to help fine-map additional discover new ASD risk
loci. This general research strategy can also be applied to
other disease gene studies.
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